SEC Filing Summary
Filing identity: The submitted filing is Selecta Biosciences, Inc.’s Form 10-K for the fiscal year ended December 31, 2018, not Cartesian Therapeutics, Inc. The filing includes unaudited fourth-quarter data but is an annual report rather than a standalone “2018 Q4” filing.
Business Context and Reporting Period
Selecta was a clinical-stage biopharmaceutical company developing its ImmTOR biodegradable nanoparticle platform to induce antigen-specific immune tolerance and reduce anti-drug antibodies against biologic therapies. Its lead candidate, SEL-212, combined ImmTOR with pegadricase for chronic refractory gout. Additional programs focused on gene therapy, including SEL-302 for methylmalonic acidemia, SEL-313 for OTC deficiency, and a CureCN collaboration for Crigler-Najjar syndrome.
The company had no approved products or product sales. Operations and revenue were dependent on research grants, collaborations, equity financing and debt. The fiscal year ended December 31, 2018; quarterly financial data show fourth-quarter revenue of $0.9 million and a net loss of $14.7 million.
Key Financial Metrics
| Metric | FY 2018 | FY 2017 | Change |
|---|---|---|---|
| Grant and collaboration revenue | $0.9 million | $0.2 million | Up $0.7 million |
| Research and development expense | $47.7 million | $45.2 million | Up 6% |
| General and administrative expense | $18.2 million | $18.8 million | Down 3% |
| Total operating expenses | $65.9 million | $64.0 million | Up 3% |
| Loss from operations | $65.0 million | $63.8 million | Higher loss |
| Net loss | $65.3 million | $65.3 million | Essentially unchanged |
| Basic and diluted loss per share | $2.92 | $3.20 | Improved per share due to higher share count |
| Cash used in operating activities | $59.2 million | $52.0 million | Higher use of cash |
| Cash, cash equivalents and short-term investments | $37.4 million | $96.6 million | Down $59.2 million |
| Loans payable | $21.4 million | $21.0 million | Similar balance |
| Accumulated deficit | $280.4 million | $216.9 million | Increased $63.5 million |
Operating margin was deeply negative because revenue was immaterial relative to operating expenses. The company reported total stockholders’ deficit of $5.4 million at year-end, compared with stockholders’ equity of $51.8 million at December 31, 2017.
Clinical and Operating Developments
- SEL-212 Phase 2 dosing was completed for 152 patients as of December 17, 2018. Approximately 66% of evaluable patients receiving five monthly combination doses maintained serum uric acid below 6 mg/dL through week 20.
- Approximately 81% of evaluable patients receiving up to 0.15 mg/kg ImmTOR with pegadricase maintained serum uric acid control below 6 mg/dL at week 12.
- Approximately 29% of SEL-212 patients reported a gout flare during the first month, compared with 50% in pegadricase-only control cohorts before those cohorts were stopped for loss of efficacy and safety.
- The company planned to begin enrollment in the COMPARE head-to-head Phase 2 trial against Krystexxa in the first quarter of 2019, with interim six-month data expected in the fourth quarter of 2019 and statistical superiority data expected in the first quarter of 2020.
- The company planned to initiate Phase 3 development of SEL-212 in the fourth quarter of 2019, subject to financing and regulatory considerations.
- The FDA placed the SEL-403 oncology program on full clinical hold in November 2018 after a patient death from pneumonitis was considered probably related to ImmTOR. The company subsequently deprioritized the program.
Material Changes Versus the Prior Comparable Period
- Revenue increased 336% to $0.9 million, primarily because the company recognized the remaining $0.9 million available under an NIDA grant after receiving approval for an overhead-rate change. Revenue remained insignificant relative to expenses.
- R&D expense increased 6%, mainly from SEL-212 Phase 2 activities, Phase 3 planning, employee compensation, facilities and stock-based compensation. Spending on preclinical programs declined.
- G&A expense declined 3%, primarily because of lower patent, consulting and collaboration-license costs, partly offset by higher stock-based compensation.
- Operating cash use increased by $7.1 million, while financing cash inflows fell sharply from $66.0 million to $0.7 million because 2017 included a private placement, debt financing and Spark-related stock proceeds.
- The company adopted ASC 606 revenue recognition on January 1, 2018 using the modified retrospective method. The adoption increased opening stockholders’ equity by $1.8 million; the filing also disclosed a $2.6 million correction related to MIT payments associated with the Spark arrangement.
- All $21.0 million of principal outstanding under the 2017 term loan was classified as current because of substantial doubt about the company’s ability to continue as a going concern and the lender’s material-adverse-change provisions.
Liquidity, Debt, Outlook and Risks
At December 31, 2018, the company had $37.4 million of cash, cash equivalents and restricted cash, including $0.4 million held by its Russian subsidiary. It used $59.2 million in operating cash during 2018. In January 2019, it raised $31.3 million of net proceeds from an equity offering of 22.2 million shares, including the underwriters’ option shares.
Management stated that existing resources, including the January 2019 financing, were expected to fund operations into the first quarter of 2020 under its then-current plan. Management also stated that additional equity or other external capital would be required to conduct the planned SEL-212 Phase 3 program. The auditor and management disclosed substantial doubt regarding the company’s ability to continue as a going concern within one year after the filing date.
- Principal liquidity risks include recurring losses, negative operating cash flow, lack of product revenue and dependence on additional financing.
- The $21.0 million SVB term loan was secured by substantially all assets other than intellectual property, subject to specified rights, and included a negative pledge over intellectual property. Contractual debt payments totaled $24.4 million, including interest, through 2022.
- SEL-212 depended primarily on 3SBio in China for pegadricase supply, creating manufacturing, regulatory, geopolitical and supply-continuity risks.
- Clinical efficacy and safety remain unproven in pivotal trials, and interim Phase 2 data may not predict later results.
- Regulatory approval, manufacturing scale-up, reimbursement, intellectual-property protection and successful commercialization remain uncertain.
- The company planned a workforce reduction of approximately 36%, affecting about 17 positions, with approximately $0.5 million of expected cash restructuring charges in the first quarter of 2019.
Most Important Facts for Investors to Verify
- Confirm that the filing issuer is Selecta Biosciences, Inc., ticker SELB, rather than Cartesian Therapeutics, Inc.
- Review the going-concern disclosure, debt classification and SVB loan acceleration provisions.
- Verify the January 2019 equity offering proceeds, share issuance and resulting dilution.
- Assess whether SEL-212 COMPARE and Phase 3 timelines were achieved and whether later clinical data confirmed the reported Phase 2 signals.
- Review the full safety profile, including serious adverse events and the SEL-403 clinical hold.
- Evaluate dependence on 3SBio for pegadricase and the status of backup manufacturing arrangements.
- Reconcile cash runway against operating cash burn, planned clinical spending and additional capital requirements.
- Review the impact of ASC 606 adoption and the disclosed correction related to MIT payments and deferred revenue.